Patents.
Should a brand-name drug manufacturer be able to extend the life of its patent exclusivity by getting a patent on a compound that the body makes from one of its drugs? That was the question before the Court of Appeals for the Federal Circuit (CAFQ) in the recent case of Schering v. Geneva. To provid...
| Xuất bản năm: | IEEE Engineering in medicine and biology magazine 23, 1 (2004). |
|---|---|
| Tác giả chính: | |
| Định dạng: | Bài viết |
| Ngôn ngữ: | English |
| Những chủ đề: |